Onchilles Pharma has built an extensive translational dataset encompassing 11 distinct cancer types, over 50 genetically diverse cell lines, and more than 20 animal models—mirroring the key characteristics of the patients we plan to enroll in our upcoming Phase 1 clinical trial. This research demonstrates broad efficacy in CDX/PDX models derived from tumors resected from ovarian, breast, and colon cancer patients; robust immune activation in immunologically cold, warm, and hot tumors; and effectiveness against chemoresistant tumors and those that have progressed on checkpoint inhibitors. No resistance mechanism has emerged upon repeat dosing, reinforcing our confidence in translating these findings to patients.

Onchilles’ lead programs—N17350 (NEU-001) for tumor-directed delivery and NEU-002 for intravenous administration—embody these therapeutic characteristics and have the potential to transform cancer treatment by delivering broad tumor-killing capabilities with immune preservation, an unmet need not addressed by current cytotoxic agents or immunotherapies.

Onchilles’ pipeline addresses a broad spectrum of cancers, including head & neck, skin, breast, and lung, with first-in-human trials anticipated to begin in late 2025.